Grace Therapeutics, Inc GRCE

9 billion

[Super63]

China is strategically important for Aker BioMarine to grow within its Ingredients segment. According to the latest GOED (The Global Organization for EPA and DHA Omega-3s) industry report, China’s Omega3-EPA/DHA consumer product market is estimated to be more than 9 billion USD, with an estimated annual growth rate of 9% through 2021.

[Francine01]

No clue who could be the buyer or shareholder of control of Acasti. But Yes, it could come from the Asian market. Remember in November 2017, Acasti signed a agreement with a Chinese pharma. Asian market is not bounded by FDA requirements. They could pretend 43% reduction for HTG. Aker was Neptune OM3 buyer, this could make sense if they want to commercialize Capre and do a small ph3 vs Amarin

[Normandt1965]

Asian market is huge, I'm very confident.

[Normandt1965]

Very interesting. https://lipidworld.biomedcentral.com/articles/10.1186/s12944-017-0601-8

[EternalPonzi]

That may or may not be true. The important fact is any product must be able to compete. If I am not mistaken, I believe CaPre is a relatively expensive supplement to manufacture and for now a company in France is the sole processor of the Krill Oil. The manufacturing process is extremely volatile/dangerous with extreme safety controls in place - probably why it is expensive. If the cost is too

[Super63]

You make some good points. Your knowledge of the French site gives you credibility. First, why are you still here? Short? I would not think so as you must be aware of headline risk sending this up.        Aker has a supplement site in Houston and is commercial in Asia and South America. However, Francine never has said supplements are the way to go but the

[EternalPonzi]

Negative, no short. No skin in this game anymore. I was very tempted to though when I saw it climb to over $1 so quickly. It was 100% guaranteed to pull back regardless of headline risk. On that topic, yes the pumpers are out in full force. Yahoo Finance is a classic example. The Outrageously bullish comments based on no facts have a permanent placeholder near the top of the board. I tried placing

[Super63]

So important for me to understand this point concerning endpoint data.  The value is in the lowering of A1C which the Pfizer chair study on mice suggested was promising.  If true, won't the diabetic angle send this stock soaring.  Why wouldn't big pharma be interested?   They must have the data and say this     ACST "As previously disclosed